Press releases

2018-10-08 - 07:00

Preclinical Efficacy of Genkyotex’s GKT831 in Prostate Cancer Presented at ESUR18 Meeting

2018-09-26 - 17:45

Genkyotex Announces First-Half 2018 Financial Results

2018-09-26 - 07:00

Genkyotex Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 for Primary Biliary Cholangitis

2018-09-03 - 17:45

Genkyotex Announces Positive Outcome from the Second Independent SMB Review of the Phase 2 Trial of GKT831 in PBC

2018-08-27 - 18:00

Genkyotex Announces Completion of Enrollment in Interim Analysis Cohort of Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

2018-08-20 - 20:30

Genkyotex secures an up to €7.5 million gross financing to further expand the development of its lead product

2018-07-31 - 18:00

Genkyotex Announces Investigator-Initiated Phase 2 Clinical Trial to be Conducted with GKT831 in Patients with Idiopathic Pulmonary Fibrosis

2018-07-25 - 17:45

Genkyotex Provides Update on PBC Phase 2 Trial And Reports June 30, 2018, Cash Position

2018-06-25 - 07:00

Genkyotex Expands License Agreement for Vaxiclase Platform with Serum Institute of India

2018-05-07 - 07:00

Genkyotex announces positive outcome from ISMB's first review of GKT831's phase 2 trial in PBC

2018-04-25 - 17:45

Genkyotex reports March 31, 2018 cash position and provides business update

2018-04-09 - 09:00

Genkyotex to Present Corporate Overview at H. C. Wainwright Annual Global Life Sciences Conference

2018-03-12 - 17:45

Genkyotex to Present Corporate Overview at 30th Annual ROTH Conference

2018-02-28 - 17:45

Genkyotex Announces 2017 Annual Financial Results

2018-02-20 - 18:00

Genkyotex's Lead Product Candidate, GKT831, Halts the Tumor Promoting Effect of Cancer Associated Fibroblasts

2018-01-31 - 18:00

Genkyotex reports December 31, 2017 cash position and provides business update

2017-12-21 - 18:00

Genkyotex announces its financial calendar for 2018

2017-10-26 - 18:00

Genkyotex provides business update for Q3 2017

2017-09-21 - 18:45

2017 first-half results

2017-08-03 - 17:45

Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated fibroblasts

2017-07-27 - 18:00

Genkyotex provides business update for Q2 2017

2017-06-28 - 18:00

Genkyotex Announces Investigator-Initiated Phase 2 Clinical Trial to Evaluate 48-week Treatment with GKT831 in Patients with Type 1 Diabetes and Kidney Disease

2017-06-27 - 18:00

Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

2017-05-02 - 21:15

Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis

2017-04-27 - 19:06

Genkyotex provides business update for Q1 2017

2017-03-14 - 18:00

Genkyotex to participate in the 1st Annual H.C. Wainwright NASH Investor Conference in New York, on April 3rd, 2017

2017-02-28 - 17:45

Genticel becomes “Genkyotex”: Genticel’s General Meeting approves the strategic combination with GenKyoTex SA

2017-02-28 - 08:30

2016 annual results

2017-01-31 - 20:30

Registration of Document E pertaining to the planned strategic combination between Genticel and Genkyotex

2017-01-30 - 18:00

BUSINESS UPDATE - FOURTH QUARTER 2016

2017-01-25 - 18:00

GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2017

2017-01-03 - 18:00

SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

2017-01-03 - 18:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-12-22 - 13:00

Genticel and Genkyotex Announce Intention to Enter into Strategic Combination

2016-12-13 - 18:30

GENTICEL REPORTS FINAL RESULTS OF GTL001 PHASE 2 TRIAL IN HPV16/18-INFECTED WOMEN

2016-11-30 - 08:00

GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines

2016-10-27 - 19:35

BUSINESS UPDATE - THIRD QUARTER 2016

2016-09-22 - 20:00

GENTICEL PRESENTS FIRST HALF 2016 FINANCIAL RESULTS AND UPDATES ITS OPERATIONAL OUTLOOK

2016-08-08 - 19:35

Disclosure of the total number of voting rights and shares composing the share capital

2016-08-08 - 19:35

HALF-YEAR SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

2016-07-28 - 19:35

BUSINESS UPDATE - SECOND QUARTER 2016

2016-07-07 - 20:30

Disclosure of the total number of voting rights and shares composing the share capital

2016-07-06 - 19:35

GENTICEL APPOINTS EUMEDIX AS STRATEGIC ADVISOR TO SUPPORT COMPANY'S ACCESS TO INNOVATIVE DRUG CANDIDATES

2016-06-23 - 18:45

GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

2016-06-15 - 20:30

GENTICEL TO PRESENT CLINICAL RESULTS OF GTL001 AND PRECLINICAL RESULTS OF GTL002 AT EUROGIN 2016 CONGRESS IN SALZBURG, AUSTRIA

2016-06-13 - 19:35

GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

2016-06-08 - 19:35

Disclosure of the total number of voting rights and shares composing the share capital

2016-06-01 - 20:00

GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001

2016-05-11 - 09:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-04-28 - 19:35

BUSINESS UPDATE - FIRST QUARTER 2016